Company intelligence / Profile preview

Medix Biochemica

Ownership: Private
Employees: ~240
Development stage: Commercial

Overview

Global leader providing over ~5000 high-quality antibodies, antigens, proteins and enzymes as critical raw materials to IVD manufacturers worldwide. Their products enable rapid assay development across multiple disease areas. Recent acquisitions have expanded their molecular diagnostics capabilities.

Therapeutic areas: OncologyEndocrinologyImmunologyCardiovascularInfectious Diseases
Modalities: AntibodyMonoclonal antibodyRecombinant proteinEnzyme replacement therapyAntigen
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Medix Biochemica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medix Biochemica.

Explore the full profile